The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice

Doniec, Zbigniew; Olszanecka-Glinianowicz, Magdalena; Hantulik, Piotr; Almgren-Rachtan, Agnieszka; Chudek, Jerzy

doi:10.1080/02770903.2022.2093220

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Так, в Польше в многоцентровом исследовании, в котором приняли участие 2 037 взрослых амбулаторных пациентов с астмой, оценили генерическую форму флутиказона/салметерола в порошковом ингаляторе. За время наблюдения (86 ± 30 дней) процент больных с контролируемой БА увеличился с 35,5% при первом посещении до 86,5% при третьем посещении (p < 0,001), приверженность превышала 95% [34].…”

Section: Chronic Pulmonary Diseasesunclassified

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Vizel,

Vizel

2023

Medicinskij sovet

View full text Add to dashboard Cite

Chronic broncho-obstructive pulmonary diseases – bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) – are a serious clinical problem and an economic burden for practical healthcare. The purpose of the scientific review is to track the evolution of views on the use of bronchodilators and inhaled corticosteroids (ICS) in these diseases and to analyze modern approaches to treatment based on domestic and international guidelines. COPD treatment is aimed at two pathogenetic components – inflammation of the bronchi and the formation of emphysema. The basis of basic therapy remains the use of long-acting bronchodilators of two classes. Treatment of asthma is directed primarily at chronic inflammation of the airways using long-acting bronchodilators. The basis of basic therapy for asthma is the use of inhaled glucocorticosteroids. Currently, the same combinations of bronchodilators and ICS are recommended for both asthma and COPD. One direction is based on the use of ICS with formoterol, a 12-hour drug with a fast onset, in which the drug can be used on demand. The second direction is based on the constant use of ICS/LABA only on a regular basis, but with the ability to use bronchodilators on demand. In this case, ICS with high affinity are more often used. An important component of treatment is adherence to medical prescriptions and the availability of different types of drugs for patients in real clinical practice. At present, conditions have been created in Russia for the implementation of both the treatment of patients with asthma and the treatment of patients with COPD with frequent exacerbations and eosinophilia based on import substitution with modern drugs.

show abstract

Section: Chronic Pulmonary Diseasesunclassified

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Vizel,

Vizel

2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice

Cited by 1 publication

References 16 publications

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Combined therapy of broncho-obstructive pathology: two solutions to one problem

Contact Info

Product

Resources

About